- $192.28m
- $125.69m
- $129.42m
Brief: Chromadex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement And $5 Million Investment
Brief: Chromadex Shares Promising Findings From Clinical Study Showcasing The Safety And Tolerability Of Nicotinamide Riboside (Nr) In Heart Failure With Reduced Ejection Fraction
ChromaDex up on JV to sell anti-ageing drug in China, raises funds
Brief: Chromadex Finalizes Commercial Joint-Venture In Asia And Announces $3.1 Million Private Placement Of Common Stock
Brief: Chromadex - Indirect Subsidiary Of Co & Hong Kong Taikuk (China) Group Entered Into A Shareholders Agreement
Brief: Sinopharm Xingsha To Introduce Chromadex’s Tru Niagen At Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)
Brief: Chromadex Announces Partnership With Mypharma2go Corp
U.S. STOCKS ON THE MOVE-Envista, Bed Bath & Beyond, United Parcel Service
U.S. STOCKS ON THE MOVE-Astra Space, Ammo, Chimerix
U.S. STOCKS ON THE MOVE-Pinduoduo, NetApp, Clean Energy Fuels
Wainwright sees slower-than-expected revenue growth for ChromaDex; cuts PT
Brief: Chromadex Corp Announced U.S. Ptab's Decision To Reject Thorne Research Attempt To Invalidate The 807 Patent
Chromadex Corp reports results for the quarter ended in June - Earnings Summary
Brief: Chromadex Q2 Sales $16.7 Million
Chromadex Corp expected to post a loss of 8 cents a share - Earnings Preview
Chromadex Corp expected to post a loss of 8 cents a share - Earnings Preview
Brief: ChromaDex Signs Sinopharm Xingsha Agreement To Accelerate Cross-Border Sales Of Tru Niagen Into Mainland China
Brief: ChromaDex Partners With Juvenis For Cross-Border Sales Of Tru Niagen Into South Korea
Brief: Chromadex Announces Agreement To Launch Commercial Joint Venture In Mainland China